Back to Trials
NCT06834594PHASE4Recruiting

Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome

Children's Mercy Hospital Kansas City

Start Date

7/31/2025

Completion Date

7/31/2026

Summary

This is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst Turner Syndrome (TS) patients with primary ovarian insufficiency (POI) prescribed hormone replacement therapy (HRT).

Eligibility Criteria

Age Range: 12 years to 20 years

Inclusion Criteria: * Diagnosis of Turner Syndrome and Primary Ovarian Insufficiency. * Prescribed adult dosing\* of transdermal or oral estradiol for estrogen replacement therapy. \*Adult dosing of will be defined per published clinical practice guidelines from the 2023 International Turner Syndrome Meeting (i.e. 50-200μg/day of transdermal estradiol, or (i.e. 50-200μg/day of transdermal estradiol or 2-4mg/day oral estradiol). * Have achieved menarche. Exclusion Criteria: * Disclosure of sexual activity and desire for contraception. * Having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place. * Having received depot medroxyprogesterone within one year prior to study recruitment. * Non-English or non-Spanish speaking.

Interventions

DRUG

Micronized progesterone 200 MG

DRUG

Micronized Progesterone 100 MG

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Turner SyndromePrimary Ovarian Insufficiency (Poi)

Locations

Children's Mercy Hospital

Kansas City, Missouri 64108

United States